Heritable and cancer risks of exposures to anticancer drugs: Inter- species comparisons of covalent deoxyribonucleic acid-binding agents

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 400, Issue 1-2, 1998, Pages 509-540

  Vogel, Ekkehart W ^a   Barbin, Alain ^b   Nivard, Madeleine J M ^a   Stack, H Frank ^c   Waters, Michael D ^d   Lohman, Paul H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c INTEGRATED LABORATORY SYSTEMS   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Anticancer drug; Covalent DNA binding agent; Heritable and cancer risk

Indexed keywords

ALKANESULFONIC ACID; ALTRETAMINE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CHLORMETHINE DERIVATIVE; CHLOROZOTOCIN; CISPLATIN; CROSS LINKING REAGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; DIMETHYLNITROSAMINE; EPOXIDE; FOTEMUSTINE; LOMUSTINE; MELPHALAN; METHYLNITROSOUREA; MITOMYCIN C; NITROSOUREA DERIVATIVE; PHOSPHORAMIDE MUSTARD; PLATINUM DERIVATIVE; PROCARBAZINE; STREPTOZOCIN; THIOTEPA; TREOSULFAN; TROFOSFAMIDE; UNINDEXED DRUG;

ARTICLE; CANCER RISK; DNA BINDING; DNA REPAIR; DROSOPHILA; GENETIC RISK; GENOTOXICITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENICITY TESTS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CROSS-LINKING REAGENTS; DATABASES, FACTUAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES; GERM CELLS; HUMANS; LETHAL DOSE 50; MEIOSIS; MUTAGENICITY TESTS; MUTATION; NEOPLASMS, SECOND PRIMARY; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SPECIES SPECIFICITY;

EID: 0032565515     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00060-8     Document Type: Article

References (143)

1. [1] ICPEMC, Mutagenesis testing as an approach to carcinogenesis, Mutat. Res. 99 (1982) 73-91, Committee 2 Final Report.
2. [2] ICPEMC, Screening strategies for chemicals that are potential germ-cell mutagens in mammals, Mutation Res. 114 (1983) 117-177, Committee 1 Final Report.
3. [3] M.D. Waters, H.J. Stack, M.A. Jackson, B.A. Bridges, I.-D. Adler, The performance of short-term tests in identifying germ-cell mutagens - a qualitative and quantitative analysis, Mutation Res. 341 (1994) 109-131.
4. [4] M.D. Waters, H.F. Stack, A.L. Brady, P.H.M. Lohman, L. Haroun, H. Vainio, Use of computerized data listing and activity profiles of genetic and related effects in the review of 195 compounds, Mutation Res. 205 (1988) 295-312.
5. [5] M.D. Waters, H.F. Stack, N.B. Garrett, M.A. Jackson, The genetic activity profile database, Environ. Health Perspect. 96 (1991) 41-45.
6. [6] M.A. Jackson, H.F. Stack, M.D. Waters, Genetic activity profiles of anticancer drugs, Mutation Res. 355 (1996) 171-208.
7. [7] D.J. Brusick, J. Ashby, F.J. de Serres, P.H.M. Lohman, T. Matsushima, B.E. Matter, M.L. Mendelsohn, D.H. Moore II, S. Nesnow, M.D. Waters, A method for combining and comparing short-term genotoxicity test data: preface, a report from ICPEMC Committee 1, Mutation Res. 266 (1992) 1-6.
8. [8] P.H.M. Lohman, M.L. Mendelsohn, D.H. Moore II, M.D. Waters, D.J. Brusick, J. Ashby, W.J.A. Lohman, A method for comparing and combining short-term genotoxicity test data: the basic system, Mutation Res. 266 (1992) 7-25.
9. [9] M.L. Mendelsohn, D.H. Moore II, P.H.M. Lohman, A method for comparing and combining short-term genotoxicity test data: results and interpretation, Mutation Res. 266 (1992) 43-60.
10. [10] D.H. Moore, M.L. Mendelsohn, P.H.M. Lohman, A method for comparing and combining short-term genotoxicity test data: the optimal use of dose information, Mutation Res. 266 (1992) 27-42.
11. 6:7-alkylguanine ratio in DNA with carcinogenic potency in rodents, Mutation Res. 110 (1983) 181-219.
12. 50) in rodents: a comparison of mono- and bi-functional alkylating agents and vinyl chloride metabolites, Mutation Res. 215 (1989) 95-107.
13. [13] C.G. Swain, C.B. Scott, Quantitative correlation of relative rates: comparison of hydroxide ion with other nucleophilic reagents towards alkyl halides, esters, epoxides and acyl halides, J. Am. Chem. Soc. 75 (1953) 141-147.
14. [14] E.W. Vogel, A. Barbin, M.J.M. Nivard, H. Bartsch, Nucleophilic selectivity of alkylating agents and their hypermutability in Drosophila as predictors of carcinogenic potency in rodents, Carcinogenesis 11 (1990) 2211-2217.
15. [15] L. Ehrenberg, U. Lundquist, S. Osterman, B. Sparrman, On the mutagenic action of alkanesulfonic esters in barley, Hereditas 56 (1966) 277-305.
16. [16] S. Osterman-Golkar, L. Ehrenberg, C.A. Wachtmeister, Reaction kinetics and biological action in barley of monofunctional methanesulphonic esters, Radiat. Bot. 10 (1997) 303-327.
17. [17] I. Quinto, M. Radman, Carcinogenic potency in rodents vs. genotoxic potency in E. coli: a correlation analysis of bifunctional alkylating agents, Mutation Res. 181 (1987) 235-242.
18. [18] I. Quinto, L. Tennenbaum, M. Radman, Genotoxic potency of monofunctional alkylating agents in E. coli: comparison with carcinogenic potency in rodents, Mutation Res. 228 (1990) 177-185.
19. [19] T. Roldán-Arjona, F.L. Luque-Romero, M. Ruiz-Rubio, C. Pueyo, Quantitative relationship between mutagenic potency in the Ara test of Salmonella typhimurium and carcinogenic potency in rodents, Carcinogenesis 11 (1990) 975-980.
20. [20] E.W. Vogel, M.J.M. Nivard, L.A.B. Ballering, H. Bartsch, A. Barbin, J. Nair, M.A. Comendador, L.M. Sierra, I. Aguirrezabalaga, L. Tosal, L. Ehrenberg, R.P.P. Fuchs, R. Janel-Bintz, G. Maenhaut-Michel, R. Montesano, J. Hall, H. Kang, M. Miele, J. Thomale, K. Bender, J. Engelbergs, M.F. Rajewsky, DNA damage and repair in mutagenesis and Carcinogenesis: implications of structure-activity relationships for cross-species extrapolation, Mutation Res. 353 (1996) 177-218.
21. [21] J.K. Lawley, D.H. Phillips, DNA adducts from chemotherapeutic agents, Mutation Res. 355 (1996) 13-40.
22. [22] W.B. Pratt, R.W. Ruddon, W.D. Ensinger, J. Maybaum, The Anticancer Drugs, Oxford Univ. Press, Oxford, 1994, pp. 1-352.
23. [23] E.W. Vogel, A.T. Natarajan, DNA damage and repair in somatic and germ-cells in vivo, in: Fundamental and Molecular Mechanisms of Mutagenesis, Mutation Res. Vol. 330, 1995, pp. 183-208.
24. [24] IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vols. 1-69, International Agency for Research on Cancer, Lyon, 1972-1997.
25. [25] A. Gilman, F.S. Philips, The biological actions and therapeutic applications of β-chloroethyl amines and sulfides, Science 103 (1946) 409.
26. [26] I.H. Krakoff, Cancer chemotherapeutic agents, Ca, A J. Clinicians 37 (1987) 93.
27. [27] N.B. Garrett, H.F. Stack, M.R. Gross, M.D. Waters, Analysis of the spectra of genetic activity produced by known or suspected human carcinogens, Mutation Res. 134 (1984) 89-111.
28. [28] N.B. Garrett, H.F. Stack, M.D. Waters, Evaluation of the genetic activity profiles of 65 pesticides, Mutation Res. 168 (1986) 301-325.
29. [29] L.A. Zwelling, J. Filipski, K.W. Kohn, Effects of thiourea on survival and DNA cross-link formation in cells treated with Pt(II) complexes, L-phenylalanine mustard and bis(22-chloroethyl)melamine, Cancer Res. 39 (1979) 4989-4995.
30. [30] A.T.M. Marcelis, J. Reedijk, Binding of platinum compounds to nucleic acids with respect to the anti-tumor activity of cis-diaminedichlorplatinum(II) and derivatives, Red. Trav. Chim. Pays-Bas 102 (1983) 121-129.
31. [31] A.C.M. Plooy, M. van Dijk, F. Berends, P.H.M. Lohman, Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II), Cancer Res. 45 (1985) 4178-4184.
32. [32] G. Eisenbrand, C. Pfeiffer, W. Tang, DNA adducts of N-nitrosoureas, in: K. Hemminki, A. Dipple, D.E.G. Shuker, F.F. Kadlubar, D. Segerbäck, H. Bartsch (Eds.), DNA Adducts: Identification and Biological Significance, IARC Sci. Publ. 125, Lyon, IARC, 1994, pp. 277-293.
33. [33] A.T. Natarajan, R.J. Preston, V. Dellarco, L. Ehrenberg, W. Generoso, S. Lewis, A.D. Tates, Ethylene oxide: evaluation of genotoxicity data and an exploratory assessment of genetic risk, Mutation Res. 330 (1995) 55-70.
34. [34] R.J. Preston, R.F. Timothy, A.P. Leber, R.L. Sielken Jr., J.A. Swenberg, Reconsideration of the genetic risk assessment for ethylene oxide exposures, Environ. Mol. Mutagen. 26 (1995) 189-202.
35. [35] D. Segerbäck, S. Osterman-Golkar, B. Molholt, R. Nilsson R, In vivo tissue dosimetry as a basis for cross-species extrapolation in cancer risk assessment of propylene oxide, Regul. Toxicol. Pharmacol. 20 (1994) 1-14.
36. [36] F. Pacchierotti, I.-D. Adler, D. Anderson, M. Brinkworth, N.A. Demopoulos, J. Lähdetie, S. Osterman-Golkar, K. Peltonen, A. Russo, A. Tates, R. Waters, Genetic effects of 1,3-butadiene and associated risk for heritable damage, Mutation Res. 397 (1998) 93-115.
37. [37] D.T. Beranek, Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents, Mutation Res 231 (1990) 11-30.
38. [38] B. Singer, D. Grunberger, Molecular Biology of Mutagens and Carcinogens, Plenum, New York, 1983, pp. 1-347.
39. [39] C.J. Michejda, R.H. Smith, Jr., M.B. Kroeger Koepke, DNA alkylation by triazenes and related compounds, in: K. Hemminki, A. Dipple, D.E.G. Shuker, F.F. Kadlubar, D. Segerbäck, H. Bartsch (Eds.), DNA Adducts: Identification and Biological Significance, IARC Sci. Publ. 125, Lyon, IARC 1994, pp. 323-337.
40. [40] U.H. Ehling, A. Neuhäuser-Klaus, Induction of specific-locus and dominant-lethal mutations by cyclophosphamide and combined cyclophosphamide-radiation treatment in male mice, Mutation Res. 199 (1988) 21-30.
41. [41] U.H. Ehling, A. Neuhäuser-Klaus, Induction of specific-locus and dominant-lethal mutations in male mice by diethyl sulfate (DES), Mutation Res. 199 (1988) 191-198.
42. [42] U.H. Ehling, A. Neuhäuser-Klaus, Induction of specific-locus and dominant lethal mutations in male mice by chlormethine, Mutation Res. 227 (1989) 81-89.
43. [43] U.H. Ehling, A. Neuhäuser-Klaus, Induction of specific-locus and dominant lethal mutations in male mice in the low dose range with methyl methanesulfonate (MMS), Mutation Res. 230 (1990) 61-70.
44. [44] U.H. Ehling, A. Neuhäuser-Klaus, Induction of specific-locus mutations and dominant lethal mutations in male mice by 1-methyl-1-nitrosourea (MNU), Mutation Res. 250 (1991) 447-456.
45. [45] U.H. Ehling, A. Neuhäuser-Klaus, Induction of specific-locus and dominant mutations by trophosphamide, Mutation Res. 307 (1994) 229-236.
46. [46] U.H. Ehling, I.-D. Adler, J. Favor, A. Neuhäuser-Klaus, Induction of specific-locus and dominant lethal mutations in male mice by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), Mutation Res. 379 (1997) 211-218.
47. [47] M.D. Shelby, Selecting chemicals and assays for assessing mammalian germ cell mutagenicity, Mutation Res. 352 (1996) 159-167.
48. [48] S. Abrahamson, F.E. Würgler, C. De Jongh, H.U. Meyer, How many loci on the X-chromosome of Drosophila melanogaster can mutate to recessive lethals, Environ. Mutagen. 2 (1980) 447-453.
49. [49] E.W. Vogel, Nucleophilic selectivity of carcinogens as a determinant of enhanced mutational response in excision repair-defective strains in Drosophila: effects of 30 carcinogens, Carcinogenesis 10 (1989) 2093-2106.
50. [50] J.A. Zijlstra, E.W. Vogel, The ratio of induced recessive lethals to ring-X loss has prognostic value in terms of functionality of chemical mutagens in Drosophila melanogaster, Mutation Res. 201 (1988) 27-38.
51. [51] E.W. Vogel, J.A. Zijlstra, M.J.M. Nivard, A genetic method for classification of genotoxins into monofunctional or cross-linking agents, Environ. Mol. Mutagen. 21 (1993) 319-331.
52. [52] J. Ashby, E.W. Vogel, H. Tinwell, R.D. Callander, D.E.G. Shuker, Mutagenicity to Salmonella, Drosophila and the mouse bone marrow of the human antineoplastic agent fotemustine: prediction of carcinogenic potency, Mutation Res. 286 (1993) 101-109.
53. [53] A. Pastink, C. Vreeken, M.J.M. Nivard, L. Searles, E.W. Vogel, Sequence analysis of N-ethyl-N-nitrosourea induced vermilion mutations on Drosophila melanogaster, Genetics 123 (1989) 123-129.
54. [54] M.J.M. Nivard, A. Pastink, E.W. Vogel, Molecular analysis of mutations in the vermilion gene of Drosophila melanogaster by methyl methanesulfonate, Genetics 131 (1992) 673-682.
55. [55] M.J.M. Nivard, A. Pastink, E.W. Vogel, Mutational spectra induced under distinct excision repair conditions by the 3 methylating agents N-methyl-N-nitrosourea, N-methyl-N′-nitro-N-nitrosoguanidine and N-nitrosodimethylamine in postmeiotic male germ cells of Drosophila, Mutat. Res. 353 (1996) 97-116.
56. [56] M.D. Waters, N.B. Garret, C.M. Covone-de Serres, B.E. Howard, H.F. Stack, Genetic toxicology of some known and suspected human carcinogens, in: F.J. de Serres (Ed.), Chemical Mutagens: Principles and Methods for Their Detection, Vol. 8, Plenum, New York, 1983, pp. 261-341.
57. [57] M.D. Waters, H.F. Stack, J.R. Rabinowitz, N.E. Garret, Genetic activity profiles and pattern recognition in test battery selection, Mutat. Res. 205 (1988) 119-138.
58. [58] L.S. Gold, C.B. Sawyer, R. Magaw, M. Backman, R. de Veciana, N.K. Hooper, W.R. Havender, J. Bernstein, R. Peto, M.C. Pike, B.N. Ames, A carcinogenic potency database of the standardized results of animal bioassays, Environ. Health Pespect. 58 (1984) 9-319.
59. [59] L.S. Gold, M. de Veciana, G.M. Backman, R. Magaw, P. Lopipero, M. Smith, M. Blumenthal, R. Levinson, L. Bernstein, B.N. Ames, Chronological supplement to the carcinogenic potency database, standardized results of animal bioassays published through December 1982, Environ. Health Perspect. 67 (1986) 161-200.
60. [60] L.S. Gold, T.H. Slone, G.M. Backman, R. Magaw, M. Da Costa, P. Lopipero, M. Blumenthal, B.N. Ames, Second chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986, Environ. Health Perspect. 74 (1987) 237-329.
61. [61] L.S. Gold, T.H. Slone, G.M. Backman, S. Eisenberg, M. Da Costa, M. Wong, N.B. Manley, L. Rohrbach, B.N. Ames, Third chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987, Environ. Health Perspect. 84 (1990) 215-285.
62. 50. A proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments, Environ. Health Perspect. 58 (1984) 1-8.
63. [63] B.L. van Duuren, L. Langseth, L. Orris, G. Teebor, N. Nelson, M. Kuschner, Carcinogenicity of epoxides, lactones and peroxy compounds: IV. Tumour response in epithelial and connective tissue in mice and rats, J. Natl. Cancer Inst. 37 (1966) 825-835.
64. [64] J.K. Dunnick, S.L. Eustis, W.W. Piegorsch, R.A. Miller, Respiratory tract lesions in F344/N rats and B6C3F1 mice after inhalation exposure to 1,2-epoxybutane, Toxicology 50 (1988) 69-82.
65. [65] National Toxicology Program, Toxicology and Carcinogenesis Studies of 1,2-epoxybutane (CAS No. 106-88-7) in F344/N rats and B6C3F1 mice (Technical Report no. 329; NIH Publication No. 88-2585) Research Triangle Park, NC, US Department of Health and Human Services, 1988.
66. [66] B. Ulland, M. Finkelstein, E.K. Weisburger, J.M. Rice, J.H. Weisburger, Carcinogenicity of industrial chemicals propylene imine and propane sultone, Nature (London) 230 (1971) 460-461.
67. [67] E.K. Weisburger, B.M. Ulland, J. Nam, J.J. Gart, J.H. Weisburger, Carcinogenicity tests of certain environmental and industrial chemicals, J. Natl. Cancer Inst. 67 (1981) 75-88.
68. [68] N.K. Hooper, A.D. Friedman, C.B. Sawyer, B.N. Ames, Carcinogenic potency: analysis, utility for human risk assessment, and relation to mutagenic potency in Salmonella (Progress Report for IARC/WHO Meeting, Lyon, October 1977), International Agency for Research on Cancer, Lyon, 1977.
69. [69] NIOSH, Registry of Toxic Effects of Chemical Substances, U.S. DHHS, 1985-1986 edn., Washington, DC, 1988.
70. [70] G.D. Clayton, F.E. Clayton (Eds.), Patty's Industrial Hygiene and Toxicology Handbook, Vol. 2A and 2B, Wiley, New York, 1981.
71. [71] L.B. Russell, P.R. Hunsicker, M.D. Shelby, Melphalan, a second chemical for which specific-locus mutation induction in the mouse is maximum in early spermatids, Mutat. Res. 282 (1992) 151-158.
72. [72] U.H. Ehling, A. Neuhäuser-Klaus, Induction of specific-locus mutations in male mice by ethyl methanesulfonate (EMS), Mutat. Res. 227 (1989) 91-95.
73. [73] J. Favor, M. Sund, A. Neuhäuser-Klaus, U.H. Ehling, A dose-response analysis of ethylnitrosourea-induced recessive specific-locus mutations in treated spermatogonia of the mouse, Mutat. Res. 231 (1990) 47-54.
74. [74] U. Ehling, Differential spermatogenic response of mice to the induction of mutations by antineoplastic drugs, Mutat. Res. 26 (1974) 285-295.
75. [75] U.H. Ehling, A. Neuhäuser, Procarbazine-induced specific-locus mutations in male mice, Mutat. Res. 59 (1979) 245-256.
76. [76] B.M. Cattanach, Chemically induced mutations in mice, Mutat. Res. 3 (1966) 346-353.
77. [77] T.A. Connors, P.J. Cox, P.B. Farmer, A.B. Foster, M. Jarman, Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide, Biochem. Pharmacol. 23 (1974) 115.
78. [78] L.B. Russell, P.B. Selby, E. von Halle, W. Sheridan, L. Valcovic, The mouse specific-locus test with agents other than radiations, interpretations of data and recommendations for future, Mutat. Res. 86 (1981) 329-354.
79. [79] E.W. Vogel, A.T. Natarajan, The relation between reaction kinetics and mutagenic action of monofunctional alkylating agents in higher eukaryotic systems: I. Recessive lethal mutations and translocations in Drosophila, Mutat. Res. 62 (1979) 51-100.
80. [80] J. Wijen, M.J.M. Nivard, E.W. Vogel, unpublished results.
81. D1 mutants on alkylation-induced genetic damage in Drosophila, Mutat. Res. 149 (1985) 193-207.
82. [82] E.W. Vogel, A.T. Natarajan, The relation between reaction kinetics and mutagenic action of monofunctional alkylating agents in higher eukaryotic systems: II. Total and partial sex-chromosome loss in Drosophila, Mutat. Res. 62 (1979) 101-123.
83. [83] E.W. Vogel, M.J.M. Nivard, Genotoxic effects of inhaled ethylene oxide, propylene oxide and butylene oxide on germ cells: sensitivity of genetic endpoints in relation to dose and repair status, Mutat. Res. (1998) in press.
84. [84] E.W. Vogel, J.A. Zijlstra, Somatic cell mutagenesis in Drosophila melanogaster in comparison with genetic damage in early germ-cell stages, Mutat. Res. 180 (1987) 189-200.
85. [85] L.B. Russell, E.M. Rinchik, Structural differences between specific-locus mutations induced by different regimes in mouse spermatogonial stem cells, Mutat. Res. 288 (1993) 187-195.
86. [86] L.B. Russell, W.L. Russell, E.M. Rinchik, P.R. Hunsicker, Factors affecting the nature of induced mutations, in: J.W. Allen, B.A. Bridges, F.M. Lyon, M.J. Moses, L.B. Russell (Eds.), Biology of Mammalian Germ Cell Mutagenesis, Banbury Report 34, Cold Spring Harbor Laboratory Press, 1990, pp. 271-289.
87. [87] J. Cizeau, M. Decoville, M. Leng, D. Locker, Deletions induced in the white and vermilion genes of Drosophila melanogaster by the antitumor drug cis-dichlorodiammineplatinum(II), Mutat. Res. 311 (1994) 31-38.
88. [88] I. Aguirrezabalaga, M.J.M. Nivard, M.A. Comendador, E.W. Vogel, The cross-linking agent hexamethylphosphoramide predominantly induces intra-locus and multi-locus deletions in postmeiotic germ cells of Drosophila, Genetics 139 (1995) 649-658.
89. [89] I. Aguirrezabalaga, M.J.M. Nivard, M.A. Comendador, E.W. Vogel, Hexamethylmelamine is a potent inducer of deletions in male germ cells of Drosophila melanogaster, Carcinogenesis 16 (1995) 2679-2680.
90. [90] P.C. Marker, K. Seung, A.E. Bland, L.B. Russell, D.M. Kingsley, Spectrum of Bmp5 mutations from germline mutagenesis experiments in mice, Genetics 145 (1997) 435-446.
91. [91] U. Ehling, Induction of gene mutations in germ cells of the mouse, Arch. Toxicol. 46 (1980) 123-138.
92. [92] L. Tosal, A. Comendador, L.M. Sierra, N-ethyl-N-nitrosourea predominantly induces mutations at AT basepairs in premeiotic germ cells of Drosophila males, Mutagenesis, (1998) in press.
93. [93] E.W. Vogel, W.G.H. Blijleven, M.J.H. Kortselius, J.A. Zijlstra, A search for some common characteristics of chemical mutagens in Drosophila, Mutat. Res. 92 (1982) 69-87.
94. [94] W.L. Russell, P.R. Hunsicker, Extreme sensitivity of one particular germ-cell stage in male mice to induction of specific-locus mutations by methylnitrosourea, Environ. Mutagen. 5 (1983) 498.
95. [95] L.B. Russell, R.B. Cummings, P.R. Hunsicker, Specific-locus mutation rates in the mouse following inhalation of ethylene oxide, and application of the results to estimation of human genetic risk, Mutat. Res. 129 (1984) 381-388.
96. [96] W.L. Russell, Dose response, repair, and no-effect dose levels in mouse germ-cell mutagenesis, in: Tazima, Y., Kondo, S., Kuroda (Eds.), Problems of Threshold in Chemical Mutagenesis, The Environmental Mutagen Society of Japan, 1984, pp. 153-160.
97. [97] O.G. Fahmy, M.J. Fahmy, Mutational mosaicism in relation to dose with the amine and amide derivatives of nitroso compounds in Drosophila melanogaster, Mutat. Res. 6 (1968) 139-154.
98. [98] R.L. Dedrick, P.F. Morrison, Carcinogenic potency of alkylating agents in rodents and humans, Cancer Res. 52 (1992) 2464-2467.
99. [99] L.B. Russell, P.R. Hunsicker, N.L.A. Cacheiro, E.M. Rinchik, Genetic, cytogenetic, and molecular analysis of mutations induced by melphalan demonstrate high frequencies of heritable deletions and other rearrangements from exposure of postspermatogonial stages of the mouse, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 6182-6186.
100. [100] S. Walles, L. Ehrenberg, Effects of β-hydroxylation and β-methoxyethylation of DNA in vitro, Acta Chem. Scand. 22 (1968) 1080-1082.
101. [101] Z. Farooqi, M. Törnqvist, L. Ehrenberg, A.T. Natarajan, Genotoxic effects of ethylene oxide and propylene oxide in mouse bone marrow cells, Mutat. Res. 288 (1993) 223-228.
102. [102] W.R. Lee, D.T. Beranek, B.J. Byrne, Dose-response relationships for methyl methanesulfonate in Drosophila melanogaster: DNA methylation per nucleotide vs. sex-linked recessive lethal frequencies, Mutat. Res. 211 (1989) 243-258.
103. [103] J.B. Boyd, J.M. Mason, A.H. Yamamoto, R.K. Brodberg, S.S. Banga, K. Sakushi, A genetic and molecular analysis of DNA repair in Drosophila, J. Cell Sci. 6 (1987) 39-60, suppl.
104. [104] M.R. Kelley, W.R. Lee, Mutagenesis in oocytes of Drosophila melanogaster: I. Scheduled synthesis of nuclear and mitochondrial DNA and unscheduled DNA synthesis, Genetics 104 (1983) 279-299.
105. [105] A.L. Spiering, W.A. Deutsch, Drosophila apurinic/apyrimidinic DNA endonucleases: characterization and mechanism of action and demonstration of a novel type of enzyme activity, J. Biol. Chem. 261 (1986) 3222-3228.
106. [106] E.W. Vogel, M.J.M. Nivard, The response of germ cells to ethylene oxide, propylene oxide, propylene imine and methyl methanesulfonate is a matter of cell-stage related DNA repair, Environ. Mol. Mutagen. 29 (1997) 124-135.
107. [107] P. Bedford, G. Eisenbrand, DNA damage and repair in the bone marrow of rats treated with four chloroethylnitrosoureas, Cancer Res. 44 (1984) 514-518.
108. [108] P.D. Lawley, P. Brookes, Interstrand cross-linking of DNA by difunctional alkylating agents, J. Mol. Biol. 25 (1967) 143.
109. [109] L.C. Erickson, M.O. Bradley, J.M. Ducore, R.A.G. Ewig, K.W. Kohn, DNA cross-linking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosourea, Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 467.
110. 16 melanoma cells, Biochem. Pharmacol. 37 (1988) 3189.
111. [111] T.P. Brent, M.E. Dolan, H. Fraenkel-Conrat, J. Hall, P. Karran, F. Laval, G.P. Margison, R. Montesano, A.E. Pegg, P.M. Potter, B. Singer, J.A. Swenberg, D.B. Yarosh, Repair of O-alkylpyrimidines in mammalian cells: a present consensus, Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1759-1762.
112. 4-ethylthymidine following exposure to methylating and ethylating hepatocarcinogens, Carcinogenesis 6 (1985) 625-629.
113. [113] E.M. Rinchik, J.W. Bangham, P.R. Hunsicker, N.L.A. Cacheiro, B.S. Kwon, I.J. Jackson, L.B. Russell, Genetic and molecular analysis of chlorambucil-induced germline mutations in the mouse, Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 1416-1420.
114. [114] J. Favor, E.W. Vogel, A.A. van Zeeland, J.G. Filser, M.L. Mendelsohn, U.H. Ehling, Methods for dose and effect assessment, in: D.J. Brusick (Ed.), Methods for Genetic Risk Assessment, Chap. 3, Lewis Publishers, Boca Raton, FL, 1994, pp. 65-123.
115. [115] M.E. Dolan, D. Scicchitano, B. Singer, A.E. Pegg, Comparison of repair of methylated pyrimidines in poly(dT) by extracts from rat liver and Escherichia coli, Biochem. Biophys. Res. Commun. 123 (1984) 324-330.
116. 4-ethylthymine preferentially form alkyl T.G pairs that do not block in vitro replication in a defined sequence, Carcinogenesis 14 (1993) 1915-1919.
117. [117] S. Mitra, B. Kaina, Regulation of repair of alkylation damage in mammalian genomes, Prog. Nucleic Acid Res. Mol. Biol. 44 (1993) 109-142.
118. [118] N.G. Fossett, P. Arbour-Reily, G. Kilroy, M. McDaniel, J. Mahmoud, A.B. Tucker, S.H. Chang, W.R. Lee, Analysis of ENU-induced mutations at the Adh locus in Drosophila melanogaster, Mutat. Res. 231 (1990) 73-85.
119. [119] B. Metzger, E. Couch, R. Wilson, On the relationship between carcinogenicity and acute toxicity, Risk Anal. 9 (1989) 169-177.
120. [120] L. Ehrenberg, S. Hussein, Genetic toxicity of some important epoxides, Mutat. Res. 86 (1981) 1-113.
121. [121] M.W. Himmelstein, J.F. Acqavella, L. Recio, M.A. Medinski, J.A. Bond, Toxicology and epidemiology of 1,3-butadiene, Crit. Rev. Toxicol. 27 (1997) 1-108.
122. [122] I.-D. Adler, J. Filser, H. Gonda, G. Schriever-Schwemmer, Dose response for 1,3-butadiene-induced dominant lethal and heritable translocations in germ cells of male mice, Mutat. Res. 397 (1998) 85-92.
123. [123] O.G. Fahmy, M.J. Fahmy, Mutagenic selectivity of carcinogenic nitroso compounds, N,N-Dimethylnitrosamine, Chem. Biol. Interactions 11 (1975) 395-412.
124. [124] C.B. Pratt, C.H. Pui, Second tumors after treatment with anticancer drugs, in: G. Powis, M.P. Hacker (Eds.), The Toxicity of Anticancer Drugs, Pergamon, Elmsford, NY, 1991, pp. 28-43.
125. [125] D.E. Bergsagel, A.J. Bailey, G.R. Langley, R.N. MacDonald, D.F. White, A.B. Miller, The chemotherapy of plasma-cell meyloma and the incidence of acute leukemia, New Engl. J. Med. 301 (1979) 743-748.
126. [126] M.A. Portugal, H.C. Falkson, K. Stevens, G. Falkson, Acute leukemia as a complication of long-term treatment of advanced breast cancer, Cancer Treat. Rev. 63 (1979) 177-181.
127. [127] J. Pedersen-Bjergaard, J. Ersboll, H.M. Sorensen, N. Keiding, S.O. Larsen, P. Philip, M.S. Larsen, H. Schultz, N.I. Nissen, Risk of acute nonlymphocytic leukemia and preleukemia in patients teated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents, Ann. Int. Med. 103 (1985) 192-200.
128. [128] J.F. Haas, B. Kittelmann, W.H. Mehnert, W. Staneczek, M. Mohner, J.M. Kaldor, N.E. Day, Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide, Br. J. Cancer 55 (1987) 213-218.
129. [129] I.C. Seo, S.A. Clark, F.D. McGovern, D.L. Clark, E.H. Johnson, Leiomyosarcoma of the urinary bladder 13 years after cyclophosphamide therapy for Hodgkin's disease, Br. J. Cancer 55 (1985) 1597-1603.
130. [130] J.R. Krause, H.Q. Ayuyang, L.D. Ellis, Secondary non-hematopoietic cancers arising following treatment of hematopoietic disorders, Br. J. Cancer 55 (1985) 512-515.
131. [131] J. Pedersen-Bjergaard, J. Ersboll, V.L. Hansen, B.L. Sorensen, K. Christoffersen, K. Hou-Jensen, N.I. Nissen, J.B. Knudsen, M.M. Hansen MM, Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma, New Engl. J. Med. 381 (1988) 1028-1032.
132. [132] L.B. Travis, R.E. Curtis, B. Glimelius, E.J. Holowaty, F.E. van Leeuwen, C.F. Lynch, A. Hagenbeek, M. Stovall, P.M. Banks, J. Adami, M.K. Gospodarowicz, S. Wacholder, P.D. Inskip, M.A. Tucker, J.D. Boice Jr., Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma, J. Natl. Cancer Inst. 87 (1995) 524-530.
133. [133] E. Levine, Transitional cell carcinoma of the renal pelvis associated with cyclophosphamide therapy, Am. J. Roentgenol. 159 (1992) 1027-1028.
134. [134] N. Einhorn N, Acute leukemia after chemotherapy (melphalan), Br. J. Cancer 41 (1979) 444-447.
135. [135] M.H. Greene, J.D. Boice, B.E. Greer, J.A. Blessing, A.J. Dembo, Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer, New Engl. J. Med. 307 (1982) 1416-1421.
136. [136] R.A. Kyle, R.V. Pierre, E.D. Bayrd, Multiple myeloma and acute myelomonocytic leukemia. Report of four cases possibly related to melphalan, New Engl. J. Med. 283 (1970) 1121-1125.
137. [137] P.D. Berk, J.D. Goldberg, M.N. Silverstein, Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy, New Engl. J. Med. 304 (1981) 441-447.
138. [138] J.M. Kaldor, N.E. Day, F. Pettersson, A. Clarke A, Leukemia following chemotherapy for ovarian cancer, New Engl. J. Med. 322 (1990) 1-6.
139. [139] R.R. Tice, H.F. Stack, M.D. Waters, Human exposures to mutagens - an analysis using the genetic activity profile database, Environ. Health Perspect. 104 (1996) 585-589, Suppl. 3.
140. [140] Physicians' Desk Reference, Medical Economics Data Production, 49th edn. Montvale, NJ, 1995.
141. [141] L.B. Russell, P.R. Hunsicker, N.L.A. Cacheiro, J.W. Bangham, W.L. Russell, M.D. Shelby, Chlorambucil effectively induces deletion mutations in mouse germ cells, Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 3704-3708.
142. [142] I. Penn, Malignancies Induced by Drug Therapy: A Review, IARC Sci. Publ. No. 78, 1986, pp. 13-27.
143. [143] P.G.N. Kramers, Trenimon-induced sex chromosome loss in Drosophila: different dose-response for ring-X as compared to rod-X loss and Y-marker loss, Mutat. Res. 142 (1985) 29-35.